HCA Healthcare (HCA) Earnings Date & Reports

HCA Healthcare announced financial results for the first quarter ended March 31, 2026. Revenues reached $19.109 billion, a 4.3% increase from $18.321 billion in Q1 2025, driven by a 3.1% rise in same-facility revenue per equivalent admission, partially offset by softer volumes. Net income attributable to HCA Healthcare totaled $1.620 billion, up 0.6% year-over-year, while diluted EPS climbed 10.9% to $7.15.

Operationally, same-facility equivalent admissions increased 1.3%, but inpatient and outpatient surgery cases declined 0.3% and 1.7%, respectively. Emergency room visits at same facilities edged up 0.3%, though overall occupancy fell to 75.5% from 76.9%. Respiratory-related admissions plunged 42% due to milder flu season, compounded by winter storm impacts. Adjusted EBITDA grew 1.9% to $3.802 billion, with the margin dipping to 19.9%.

While revenue slightly beat expectations, EPS missed the consensus by $0.04. The company reaffirmed its 2026 guidance, projecting revenues of $76.5 billion to $80 billion and diluted EPS of $29.10 to $31.50, assuming stable volumes and no major policy shifts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock discovery process.

Market Reaction and Investor Sentiment

HCA shares dropped approximately 8% in premarket trading after the Q1 release, reflecting disappointment over volumes that fell short of seasonal norms despite revenue and EPS growth. Investors interpreted the results as signaling caution on near-term demand, with lower respiratory cases and weather effects cited as drags. Sentiment turned cautious, though robust cash flows from operations—up 22% to $2.014 billion—and ongoing share repurchases of $1.571 billion provided some support.

Forward Outlook and Key Factors to Monitor

With full-year 2026 guidance reaffirmed, HCA executives highlighted adaptability amid dynamic conditions. Investors should track volume trends into Q2, particularly recovery in elective surgeries and ER visits as seasonal factors normalize.

Payer mix stability and reimbursement rates remain critical, alongside potential impacts from healthcare policy changes, such as Medicaid supplemental payments and expiring premium tax credits. Labor costs and supply chain pressures could test margins, but pricing strength—evident in 5.0% same-facility inpatient revenue per admission growth—offers a buffer.

Capital allocation stays proactive: $1.119 billion in capex (excluding acquisitions), $0.78 quarterly dividend, and $9.179 billion remaining for buybacks signal confidence. Upcoming catalysts include Q2 results in late July and any M&A (mergers and acquisitions) activity in a fragmented market. Broader industry dynamics, like hospital consolidation and outpatient shifts, will influence long-term positioning.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations